Rosetta Biosoftware Releases the Rosetta Elucidator® System Version 3.2

Rosetta Biosoftware, a global leader in life sciences informatics solutions, today announced the availability of the Elucidator system version 3.2, with major enhancements for support of SILAC and ¹⁴N/¹⁵N labeling and phosphoproteomics. The expanded suite of features empowers scientists with new workflows for biomarker discovery, verification and validation in basic and translational research.

The Elucidator system version 3.2 has already received high praise from proteomics thought leaders as a robust, streamlined, and efficient informatics system. "The Elucidator system version 3.2 is a major enabling technology for our facility. It is an essential element of our proteomics workflow, used both for small-scale studies supporting basic biological research as well as large-scale clinical studies comprised of hundreds of samples," said M. Arthur Moseley, Ph.D., Director of Proteomics, Institute for Genome Sciences & Policy, Duke University School of Medicine.

The features in Elucidator system version 3.2 expand researchers' capabilities in deep data mining, addressing a critical gap in proteomic analysis. New data analysis workflows enable scientists to discover post-translational modifications of all types, including those related to phosphoproteomics. Metabolic labeling enhancements include support for SILAC and ¹⁴N/¹⁵N labeling, expanding the differential expression toolkit.

"The newest release reiterates our commitment to making our solutions universal across multiple workflows and instrument platforms, with cutting-edge tools that drive our customers' research productivity," says Yelena Shevelenko, General Manager of Rosetta Biosoftware.

These features and others will be demonstrated via a Rosetta Biosoftware Webinar on December 10 at 8:00 AM Pacific Standard Time. For more information, visit www.rosettabio.com/events.

About the Rosetta Elucidator System

The Elucidator system's advanced data management capabilities allow users to effectively organize and analyze complex LC/MS expression data. The application serves as a core integrator for proteomics research by supporting many instrument vendors' raw files and universal database search engines, while providing support for multiple workflows. In addition, it provides a suite of advanced statistical analysis and visualization tools for data mining and discovery of proteins that are differentially expressed among different phenotypes or drug treatments. For more information, visit www.rosettabio.com/products/elucidator.

About Rosetta Biosoftware

Rosetta Biosoftware, Seattle, Wash., is a leading provider of informatics solutions for life science research. Its comprehensive software solutions, including the Rosetta Resolver, Elucidator, and Syllego systems, empower life scientists with advanced, scalable, and easy-to-use analysis platforms that accelerate discovery research. Rosetta Biosoftware is a business unit of Rosetta Inpharmatics LLC, a wholly owned subsidiary of Merck & Co., Inc. More information about Rosetta Biosoftware is available at www.rosettabio.com.

Forward-Looking Statements

This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Neither Rosetta Inpharmatics nor Merck & Co., Inc. undertakes any obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect the business of Merck & Co., Inc. including, among others, the extent to which Rosetta Inpharmatics' technology platform can be used in drug discovery programs, uncertainty of market acceptance of Rosetta Inpharmatics' technologies, ability to compete against existing technologies, and those mentioned in the cautionary statements in Item 1 of Merck’s Form 10-K for the year ended Dec. 31, 2007 and in its periodic reports on Form 10-Q and Form 8-K (if any) which are incorporated by reference.

Rosetta Resolver and Elucidator are U.S. registered trademarks of Rosetta Inpharmatics LLC.